Morepen Laboratories reported a weak set of numbers for the first quarter of FY26, with sharp year-on-year declines across all key financial metrics.
The company’s net profit slumped 68.5% to ₹11.4 crore, down from ₹36.2 crore in the corresponding quarter last year. Revenue for the quarter stood at ₹425 crore, registering a decline of 6.6% compared to ₹455 crore in Q1 FY25.
EBITDA came in at ₹24 crore, down 53.4% from ₹51.5 crore a year ago. Consequently, the EBITDA margin also saw a substantial contraction, falling to 5.7% from 11.3% in the same period last year.
In the meantime, Morepen’s shares slipped around 4% post results. The stock opened at ₹57.20 and touched an intraday low of ₹51.66, compared to the previous close of ₹56.55. It currently trades well below its 52-week high of ₹100.90, but remains above the 52-week low of ₹42.
